Leukemia
News
Sprycel® Superior to High-dose Gleevec® in Gleevec-resistant CML
(07/01/2009)
Sprycel® (dasatinib) produces a higher response rate and improves progression-free survival in patients with chronic myeloid leukemia (CML) who have grown resistant to Gleevec® (imatinib), according to the results of a study published early online in Cancer.
Eliminating Preventive Radiation May Benefit Children with ALL
(06/26/2009)
Children with acute lymphoblastic leukemia (ALL) who are treated with effective, risk-adjusted chemotherapy regimens have good outcomes and may safely be able to avoid preventive radiation therapy to the brain. These results were published in the New England Journal of Medicine.
Formaldehyde Exposure May Increase Risk of Blood and Lymphatic Cancers
(06/23/2009)
Industrial workers who are exposed to formaldehyde may be at an increased risk of dying from blood and lymphatic cancers, particularly myeloid leukemia but also Hodgkin’s lymphoma and multiple myeloma, according to the results of a study published in the Journal of the National Cancer Institute.
Compressed Dose-dense Induction with S-HAM Effective and Less Toxic for AML Patients
(05/05/2009)
The dose-dense induction regimen S-HAM (sequential high-dose cytarabine [Cytosar®] and mitoxantrone [Novantrone®] followed by Neulasta® [pegfilgrastim]) delivered in two induction cycles over 11-12 days instead of 25-29 days is highly effective in patients with acute myeloid leukemia (AML) and results in a shorter period of low blood cell counts. The results of this study were published in Blood.
Abnormal Cells Identified in Blood Years Before Diagnosis of CLL
(03/09/2009)
According to the results of a study published in the New England Journal of Medicine, chronic lymphocytic leukemia (CLL) appears to be preceded by a condition known as monoclonal B-cell lymphocytosis (MBL).
More
Leukemia
Cancer News...